{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:32Z","timestamp":1786986932822,"version":"build-2736575974"},"reference-count":28,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Mass Spectrometry"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clinms.2017.12.002","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T03:19:32Z","timestamp":1513394372000},"page":"6-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC\u2013MS\/MS"],"prefix":"10.21627","volume":"7","author":[{"given":"M.","family":"Conti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Matulli Cavedagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ramazzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Calza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Badia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guardigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Verucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4811","reference":[{"key":"10.1016\/j.clinms.2017.12.002_b0005","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clinms.2017.12.002_b0010","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J. Hepatol. 55 (2011) 245\u2013264. doi:10.1016\/j.jhep.2011.02.023.","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"10.1016\/j.clinms.2017.12.002_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinms.2017.12.002_b0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinms.2017.12.002_b0025","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinms.2017.12.002_b0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/COH.0b013e32834b54dc","article-title":"Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions","volume":"6","author":"Seden","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.clinms.2017.12.002_b0035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/FTD.0000000000000161","article-title":"Does therapeutic drug monitoring of ribavirin in HCV genotype 3 treatment with sofosbuvir and ribavirin still have a role?","volume":"37","author":"Brochot","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinms.2017.12.002_b0040","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/ajg.2013.140","article-title":"Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1","volume":"108","author":"Stickel","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clinms.2017.12.002_b0045","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1128\/AAC.00281-13","article-title":"Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir","volume":"57","author":"Aouri","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinms.2017.12.002_b0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpba.2013.02.025","article-title":"A UPLC\u2013MS\/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir","volume":"78\u201379","author":"D\u2019Avolio","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinms.2017.12.002_b0055","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clinms.2017.12.002_b0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpba.2015.01.027","article-title":"Multiplexed LC\u2013MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinms.2017.12.002_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jchromb.2016.04.036","article-title":"Simultaneous determination of 14 antiviral drugs and relevant metabolites in chicken muscle by UPLC\u2013MS\/MS after QuEChERS preparation","volume":"1023\u20131024","author":"Mu","year":"2016","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed Life Sci."},{"key":"10.1016\/j.clinms.2017.12.002_b0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.talanta.2016.08.050","article-title":"Online solid phase extraction and liquid chromatography-mass spectrometric determination of nucleoside drugs in plasma","volume":"161","author":"Wang","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/j.clinms.2017.12.002_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2014.10.005","article-title":"A validated LC\u2013MS\/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma","volume":"973","author":"Yuan","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed Life Sci."},{"key":"10.1016\/j.clinms.2017.12.002_b0080","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/FTD.0000000000000189","article-title":"Determination of the HCV protease inhibitor telaprevir in plasma and dried blood spot by liquid chromatography-tandem mass spectrometry","volume":"37","author":"Verweij-Van Wissen","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinms.2017.12.002_b0085","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1128\/AAC.04795-14","article-title":"Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy","volume":"59","author":"Gutierrez-Valencia","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinms.2017.12.002_b0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jpba.2015.11.028","article-title":"A highly sensitive and selective LC\u2013MS\/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies","volume":"119","author":"Kandoussi","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinms.2017.12.002_b0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2014.02.028","article-title":"Determination of simeprevir: a novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"958","author":"Vanwelkenhuysen","year":"2014","journal-title":"J. Chromatogr. B, Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.clinms.2017.12.002_b0100","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clinms.2017.12.002_b0105","first-page":"157","article-title":"ISO 15189 up-to-date information and prospective view","volume":"64","author":"Shimoda","year":"2016","journal-title":"Rinsho Byori"},{"key":"10.1016\/j.clinms.2017.12.002_b0110","unstructured":"ISO 15189, ISO 15189:2012 Medical laboratories Requirements for quality and competence, Http:\/\/Www.Iso.Org\/Iso\/Catalogue_Detail?Csnumber=56115. (2012) Accessed 22\/01\/2016."},{"key":"10.1016\/j.clinms.2017.12.002_b0115","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinms.2017.12.002_b0120","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinms.2017.12.002_b0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/bio.15.251","article-title":"AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers","volume":"8","author":"Lowes","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.clinms.2017.12.002_b0130","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cca.2011.07.016","article-title":"LC\u2013MS\/MS quantitation of ribavirin in serum and identification of endogenous isobaric interferences","volume":"412","author":"Danso","year":"2011","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.clinms.2017.12.002_b0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jchromb.2006.12.038","article-title":"Ultra-performance liquid chromatography\/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma","volume":"852","author":"Wang","year":"2007","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.clinms.2017.12.002_b0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0021-9673(02)01536-4","article-title":"Validation of high-performance liquid chromatography methods for pharmaceutical analysis","volume":"987","author":"Shabir","year":"2003","journal-title":"J. Chromatogr. A"}],"container-title":["Clinical Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376999817300314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376999817300314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:47:36Z","timestamp":1770263256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376999817300314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":28,"alternative-id":["S2376999817300314"],"URL":"https:\/\/doi.org\/10.1016\/j.clinms.2017.12.002","relation":{},"ISSN":["2376-9998"],"issn-type":[{"value":"2376-9998","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC\u2013MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Clinical Mass Spectrometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinms.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}